Ellsworth Advisors »

Theravance Biopharma shares owned by Ellsworth Advisors

Quarter-by-quarter ownership of Theravance Biopharma (TBPH) shares owned by Ellsworth Advisors from 13F filings

Historical chart of Ellsworth Advisors investment in Theravance Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Theravance Biopharma held by Ellsworth Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Theravance Biopharma by Ellsworth Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $670k 33k 20.11

More positions owned by Ellsworth Advisors

Spdr Gold Tr Gold Shs (GLD)
NVIDIA Corporation (NVDA)
Harbor Etf Trust Harbor Commodity (HGER)
First Tr Exchange-traded First Tr Enh New (FTSM)
Apple (AAPL)
Alphabet Cap Stk Cl C (GOOG)
Johnson & Johnson (JNJ)
Amgen (AMGN)
Advanced Micro Devices (AMD)
Microsoft Corporation (MSFT)
Meta Platforms Cl A (META)
Anglogold Ashanti Com Shs (AU)
Cisco Systems (CSCO)
Packaging Corporation of America (PKG)
Darden Restaurants (DRI)

View all positions for Ellsworth Advisors

Top funds holding Theravance Biopharma

Madison Avenue Partners
Weiss Asset Management LP[1
Newtyn Management
BlackRock
Irenic Capital Management
Vanguard Group
Park West Asset Management
D. E. Shaw & Co
Oasis Management
Acadian Asset Management
State Street Corporation
Geode Capital Management
Dimensional Fund Advisors
Arrowstreet Capital, Limited Partnership
UBS Group

View all funds holding Theravance Biopharma